MaaT Pharma announces positive outcome from interim analysis of Phase 2b PHOEBUS trial evaluating MaaT033 in patients undergoing allo-HSCT. Data Safety Monitoring Board found no safety concerns or excessive mortality, recommending trial to continue as planned. PHOEBUS trial is largest randomized controlled study of microbiome therapy in oncology, with routine safety assessments every six months. Enrollment ongoing across 60 clinical sites in Europe, with target of 387 patients. Next DSMB safety review scheduled for Q1 2026. MaaT Pharma committed to advancing MaaT033 as potential therapeutic option for blood cancer patients undergoing allo-HSCT.

Read more at Nasdaq.: MaaT Pharma’s MaaT033 For Allo-HSCT Patients Clears Second DSMB Safety Review In Phase 2b Trial